You are here: Home » Markets » News
Business Standard

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Among sectoral indices, the Nifty Pharma index ended over 3 per cent higher led by rise in the shares of Sun Pharmaceutical Industries and Lupin.

SI Reporter  |  New Delhi 

Markets, Stocks, Shares
A share broker monitors market fluctuation

The benchmark indices ended higher on Tuesday, taking cues from their global peers and helped by pharmaceutical, information technology and financial stocks.

The S&P ended at 37,852, up 207 points while the broader Nifty50 index settled at 11,435, up 79 points.

In key stocks, the market heavyweight Reliance Industries (RIL) rose 2 per cent to Rs 1,210.95 levels on the Sun Pharmaceutical Industries too surged around 7 per cent to end at Rs 601.65.

Among sectoral indices, the Pharma index ended over 3 per cent higher led by rise in the shares of Sun Pharmaceutical Industries while index ended nearly 1 per cent up led by MindTree. The Realty index ended nearly 2 per cent led by DLF and Housing Development and Infrastructure.

Rupee

The rupee breached 70 per dollar,  hitting an all-time low on Tuesday after diving by Rs 1.09 to close at an all-time low of Rs 69.92 against the US dollar on Monday, bowing to a global rout in currencies on fears of an economic crisis in Turkey. was the biggest single-day fall in almost five years.

Global Markets

World share regained their footing on Tuesday as the threat from the collapse of the Turkish lira ebbed and reassuring German data offset signs of slowing growth in China.

Japan’s Nikkei held onto its early 1.1 per cent gain, while Australian stocks added 0.8 per cent. The Shanghai blue chip index was off 0.6 per cent and weighing on MSCI’s broadest index of Asia-Pacific shares outside Japan which eased 0.2 per cent.

(with wire inputs)

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Nifty Pharma index ends 3.21% higher. Top gainers: COMPANY LATEST PREV CLOSE GAIN() GAIN(%) SUN PHARMA.INDS. 601.80 563.90 37.90 6.72 BIOCON 589.40 571.70 17.70 3.10 DIVI'S LAB. 1154.55 1120.20 34.35 3.07 LUPIN 836.75 811.95 24.80 3.05 CIPLA 642.75 628.30 14.45 2.30

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Nifty sectoral gainers and losers

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

BSE Sensex: Sun Pharma, YES Bank, RIL among top gainers of the day

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Market at close The S&P BSE Sensex ended at 37,852, up 207 points while the broader Nifty50 index settled at 11,435, up 79 points.

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

External factors, selective intervention by RBI led to rupee's fall: Garg The government on Tuesday blamed "external factors" for the rupee's fall to an all-time low against the US dollar and said there is nothing to worry. Economic Affairs Secretary Subhash Chander Garg said external factors may ease going forward. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Sun Pharma rallies 7% as Q1 profit beats Street estimates Shares of Sun Pharmaceutical Industries have rallied 7% to Rs 600 per share on the BSE after the pharmaceutical company reported a better-than-expected consolidated net profit at Rs 9.83 billion in June quarter (Q1FY19). The company had posted a loss of Rs 4.25 billion in the same quarter year ago. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

MCX to launch rubber futures on Aug 16 Leading commodity bourse MCX today announced launching of the rubber futures from August 16 to provide hedging to the entire value chain in the rubber industry. The MCX said it will offer four futures contracts in rubber with each ending September, October, November and December, respectively, an official statement said. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Sebi's consent route to ease pending case load yields success in FY18   Markets regulator Securities and Exchange Board of India (Sebi) settled double the number of cases through the so-called consent mechanism in 2017-18, compared to the previous fiscal. According to data, Sebi resolved 200 cases through the consent route last fiscal as against 103 in 2016-17.   The amount earned by Sebi as settlement fees also saw a more than two-fold increase to Rs 300 million in FY18, compared to Rs 135 million in FY17. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

STOCK ALERT Cadila Healthcare nears 52-week low post June quarter results   Shares of Cadila Healthcare have slipped 5% to Rs 336 per share, extending their 6% decline on Monday on the BSE, after the company reported a lower-than-expected 30% year on year (YoY) growth in net sales at Rs 28.94 billion in the June quarter (Q1FY19) due to lower US sales.   The company’s net profit grew by 233% YoY to Rs 4.60 billion in Q1FY19 due to other income of Rs 1.01 billion. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Market Check INDEX LATEST PREVIOUS CHANGE CHANGE(%) NIFTY 50 11439.80 11355.75 84.05 0.74 NIFTY 500 9718.75 9656.50 62.25 0.64 NIFTY MIDCAP 100 19114.50 19012.40 102.10 0.54 NIFTY SMALL 100 7473.65 7463.65 10.00 0.13 INDIA VIX 13.23 13.40 -0.17 -1.27 > More on NSE Indices

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

COMMENT Aditi Nayar, Principal economist, ICRA on rupee, inflation As expected, a favourable base effect for primary food items and minerals, dampened the WPI inflation to 5.1% in July 2018 from 5.8% in June 2018, mirroring the extent of the correction displayed by the CPI inflation print. Contagion related to the crisis in Turkey has seeped into other emerging market currencies, causing the INR to depreciate as well. Factors such as broader emerging market currency movement, dollar strength, and the trend in crude oil prices will drive the outlook for the INR in the immediate term, which will have an impact on the landed cost of imports as well as various commodity prices, thereby transmitting into the WPI inflation. Given the prevailing risk aversion in the global markets, the rupee is expected to remain volatile going ahead, and average 68.5/USD in FY2019

First Published: Tue, August 14 2018. 08:15 IST
RECOMMENDED FOR YOU

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Among sectoral indices, the Nifty Pharma index ended over 3 per cent higher led by rise in the shares of Sun Pharmaceutical Industries and Lupin.

The benchmark indices ended higher on Tuesday, taking cues from their global peers and helped by pharmaceutical, information technology and financial stocks.

The S&P ended at 37,852, up 207 points while the broader Nifty50 index settled at 11,435, up 79 points.

In key stocks, the market heavyweight Reliance Industries (RIL) rose 2 per cent to Rs 1,210.95 levels on the Sun Pharmaceutical Industries too surged around 7 per cent to end at Rs 601.65.

Among sectoral indices, the Pharma index ended over 3 per cent higher led by rise in the shares of Sun Pharmaceutical Industries while index ended nearly 1 per cent up led by MindTree. The Realty index ended nearly 2 per cent led by DLF and Housing Development and Infrastructure.

Rupee

The rupee breached 70 per dollar,  hitting an all-time low on Tuesday after diving by Rs 1.09 to close at an all-time low of Rs 69.92 against the US dollar on Monday, bowing to a global rout in currencies on fears of an economic crisis in Turkey. was the biggest single-day fall in almost five years.

Global Markets

World share regained their footing on Tuesday as the threat from the collapse of the Turkish lira ebbed and reassuring German data offset signs of slowing growth in China.

Japan’s Nikkei held onto its early 1.1 per cent gain, while Australian stocks added 0.8 per cent. The Shanghai blue chip index was off 0.6 per cent and weighing on MSCI’s broadest index of Asia-Pacific shares outside Japan which eased 0.2 per cent.

(with wire inputs)

image
Business Standard
177 22